Our Milestones & Accomplishments
Initiated stage 1 hemangiosarcoma (HSA) therapeutic vaccine trial 
Published the results of our stage 1 diagnostic, demonstrating high sensitivity for accurately detecting 5 common canine cancers
Initiated a research trial for our first product, StageOne Plus, a multi-cancer, multi-stage dog diagnostic test
Created proprietary database of all human and pet mRNA-derived neoantigens (REDNs)
Developed a process for functionally screening for immunogenic, shared neoantigens on our Discovery chips
Validated diagnostic sensitivity and specificity for stage 1 tumor detection on our Diagnostic chips
Established scalable manufacturing of Diagnostic chips
Completed 800+ dog 5 year VACCS trial showing safety and efficacy of our vaccine
Completed extension year of our VACCS trial
Collected largest bank of blood from pets with stage 1 tumors
Published pre-clinical studies validating vaccine platform
Product Timeline
Calviri has made discoveries, inventions and built technical platforms that will spur the formation of new companies encompassing diagnostics and immunologics (vaccines) for both animals and humans.
.png)
.png)
Presentations, Webinars & Events
Calviri’s insights and innovations allow us to make diagnostics and vaccines that have already shown the potential to enormously impact human and canine health, globally. These products are all based on our unique tumor neoantigens and peptide microchips. They are the key. Our dog diagnostic tests will drive partnership, licensing and spinout opportunities. Our therapeutic vaccines will serve as companion products. The preventative vaccines open new ways to battle cancer. Calviri’s neoantigens and microchips make ending cancer possible.
Previous Presentations & Events
2025
WHO mRNA Conference in Brussels (October)
Cancer at the Crossroads: West (October)
Kansas City Animal Health Conference (August)
VetHealth Global Conference (June)
BIO International (June)
UBS Global Networking (May)
Animal Health, Nutrition & Technology Innovation (May)
Phoenix Global Forum (April)
Future of Healthcare Symposium at Pepperdine University (April)
Venture Madness (February)
Event
​
Event
Event
​
Event
​
Event
​
Event
​
Event
​
Event
Event
Animal Health-Let's End Cancer
2024
XPANSE International (November)
BIO International (June)
AACR Partnering (April)
BIO International (June)
AACR Partnering (April)
Venture Café Phoenix (April)
Phoestival of Health-PBC (April)
Cancer at the Crossroads (March)
Let's End Cancer Presentation
​
Event
​
Event
Preventive Cancer Vaccine
Event
​
Spotlight on Cancer Early Detection
Cancer Prevention​​
​
Event
2023
Next Gen Cancer Vaccine Development
Kansas City Animal Health Conference
MedInvest Oncology Investor Conference
World Vaccine Congress West Coast
Genetic Predisposition to Primary CNS Cancer
Venture Care
Senate Health Committee-State Capital
USDA
2022
World Vaccine & Immonotherapy Summit
Vaccine Summit Washington, DC
Next Generation Cancer Vaccine Development Summit
NCI Animal Model Workshop
2020
World Vaccine Congress
JP Morgan
The case for creating a broadly protective preventative cancer vaccine: Report on a large canine clinical trial testing the concept & A simple blood-based assay to predict response to immunotherapy and immune related adverse events
Event
​
Calviri aims to end cancer worldwide with a diagnostic to detect cancer early and vaccines to treat or even pervent cancer
Demonstration of a Universal Preventative Cancer Vaccine
​
A Vaccine Strategy to Prevent Cancer
​
Preventing Cancer Might Be Easier Than Most Think
​
Our work to end cancer and connection to ASU
​​
Vaccine Data for USDA
A new approach to therapeutic cancer vaccines; A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment
A New Source of Cancer NeoAntigens as the Basis for a Broadly Preventative Cancer Vaccine
​
The case for creating a broadly protective preventative cancer vaccine: Report on a large canine clinical Trial Testing the concept; A simple blood-based assay to predict response to immunotherapy and immune related adverse events
​
Animal Models for Cancer
RNA Frameshift Errors Provide New Vaccine Product Opportunities Against Cancer
Ending Death from Cancer - Calviri presents investment opportunity
2019
Arizona Bioindustry Association
Midwestern University
Molecular Med Tri-Con
Molecular Med Tri-Con
PepTalk
Going to the Dogs – How the Largest Canine Clinical Trial in History May Lead to New Hope for Humans
Shifting the paradigm in diagnosing and treating cancer
RNA generated frameshift neoantigens in tumors are useful in diagnosis and vaccination
Using a blood-based 400K frameshift peptide array to develop cancer type-specific vaccinations
A new source of neoantigens and a platform for their discovery
2018
Molecular Med Tri-Con
Immune Oncology Summit
American College of Veterinary Internal Medicine
Golden Retriever Club of America
United States Patent and Trademark Office
European NeoAG Summit
Cancer type specific FAST vaccines based on frameshift neoantigens
Tapping a new source of neoantigens: applications in therapy and diagnostics
A new blood based approach to early diagnosis of cancer
Calviri’s Technology Enables a Universal Preventative Vaccine
Inventions to effectively eradicate cancer
Shifting the paradigm in diagnosing and treating cancer
2018
Golden Retriever Club of America
An alternative source of neoantigens offers new approaches to personal and general vaccines
Contact Us
Please direct any questions or comments you have for us via our contact form below.
